CCT6A may act as a potential biomarker reflecting tumor size, lymphatic metastasis, FIGO stage, and prognosis in cervical cancer patients

OBJECTIVE: Chaperonin‐containing tailless complex polypeptide subunit 6A (CCT6A) is a critical regulator and newly identified clinical biomarker of several cancers, while its correlation with the clinical characteristics and prognosis of cervical cancer patients is unclear. Therefore, this study aimed to explore this issue. METHODS: Chaperonin‐containing tailless complex polypeptide subunit 6A expression in tumor and tumor‐adjacent tissues from 198 cervical cancer patients who underwent resection were detected by immunohistochemistry assay and reverse transcription‐quantitative polymerase chain reaction. Besides, the clinicopathological features and survival data of cervical cancer patients were collected. RESULTS: Chaperonin‐containing tailless complex polypeptide subunit 6A protein and mRNA levels were both increased in tumor tissues compared with tumor‐adjacent tissues (both p < 0.001). Receiver operating characteristic curves showed that CCT6A protein (AUC: 0.774, 95% CI: 0.729–0.819) and mRNA levels (AUC: 0.904, 95% CI: 0.874–0.934) well discriminated tumor tissues from tumor‐adjacent tissues. Besides, correlation analyses found that CCT6A protein and mRNA levels were positively correlated with lymph node metastasis and FIGO stage (all p < 0.05), apart from which CCT6A mRNA level was also positively associated with tumor size (p = 0.032). In addition, CCT6A protein and mRNA levels were negatively correlated with accumulating disease‐free survival (both p < 0.05); meanwhile CCT6A mRNA level was negatively associated with accumulating overall survival as well (p = 0.010). CONCLUSION: Chaperonin‐containing tailless complex polypeptide subunit 6A is elevated in tumor tissues, and its high expression associates with larger tumor size, lymph node metastasis, higher FIGO stage, and worse prognosis in cervical cancer patients.